Explore the latest news from Khondrion and its team.
Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the...
Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that...
Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that it has...
Designation granted for the treatment of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) syndrome. Khondrion, a...
NIJMEGEN, the Netherlands – Wednesday July 1st, 2020 Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies...
Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease and proposes potential...
We recently sat down with Kasey Woleben, Co-founder, and Sophia Zilber, Board Member and Patient Registry Director of Cure Mito Foundation, to talk...
As 2021 draws to a close, Khondrion’s CEO Jan Smeitink reflects on the past year and the continued progress Khondrion has made in its development of...
Movement, the act or process of moving, the change of place or position or posture, is a complex process under the control of many different parts...
How did you first hear about Khondrion and the work the company is doing in mitochondrial disease? Jan Smeitink and I have been colleagues since the...
How did you first hear about Khondrion and the work the company is doing in mitochondrial disease? I first heard about Khondrion from CEO Jan...
Can you explain a little about the work that International Mito Patients does? International Mito Patients (IMP) is a global network of 16 national...
